

Invega Sustenna® Review

1. You are preparing to administer Invega Sustenna® to a patient who weighs 146 pounds. What size needle will you use?
 - a. A 1-inch 23-gauge needle is recommended
2. Name the most common side effects a patient may experience when taking Invega Sustenna®.
 - a. The most common side effects are injection site reactions, sleepiness or drowsiness, dizziness, feeling restless or needing to be constantly moving, abnormal muscle movements including tremors (shaking), shuffling, uncontrolled involuntary movements, and abnormal movements of your eyes.
3. What black box warning is associated with this medication?
 - a. The black box warning is that there is increased mortality in elderly patients with dementia-related psychosis
4. What are the standard *recommended* Day 1 and Day 8 initiation dosages for a person with schizophrenia?
 - a. Day 1 = 234 mg
 - b. Day 8 = 156 mg
5. What is the standard *recommended* maintenance dosage for a patient with schizophrenia?
 - a. The standard recommended maintenance dosage is 117 mg
6. What is the correct location for administration of the Day 1 and Day 8 initiation doses?
 - a. The correct location for administration is the deltoid.
7. What are the *recommended* Day 1 and Day 8 initiation dosages for a person with a creatinine clearance of 65mL/min?
 - a. Day 1 = 156 mg

b. Day 8= 117 mg

8. What would the *recommended* maintenance dosage be for a patient with mild renal impairment?
 - a. The maintenance dose would be 78 mg
9. What is the rationale for a trial of oral paliperidone or oral or injectable risperidone before placing a patient on Invega Sustenna®?
 - a. For patients who have never taken oral paliperidone or oral or injectable risperidone, it is recommended to establish tolerability with oral paliperidone or oral risperidone prior to initiating treatment with INVEGASUSTENNA®.
10. Name three practices when preparing an intramuscular injection that ensure aseptic technique is maintained throughout the procedure.
 - a. Perform hand hygiene
 - b. Clean the medication's vial's rubber stopper with an alcohol swab before drawing up
 - c. Use a new sterile needle and syringe for drawing up and administering the medication, avoiding any contact with non-sterile surfaces.
11. Explain the rationale for obtaining consent for this psychoactive medication prior to preparing the medication for administration.
 - a. Obtaining consent ensures the patient's autonomy, promotes safety by identifying risks, and upholds legal and ethical standards before administering a psychoactive medication.